Serotonin Transporters in Alcoholism
PET Evaluation of Serotonin Transporters Using [C-11] DASB in Alcoholism
This study will compare serotonin transporter proteins in people with alcoholism and healthy volunteers to examine how these proteins may be related to the inability of people with alcoholism to appropriately regulate their alcohol consumption. Serotonin transporters regulate levels of the brain chemical serotonin. Problems in this regulation have been implicated in alcoholism.
Healthy normal volunteers and people who suffer from alcoholism who are between 18 and 75 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, psychiatric diagnostic interview, blood and urine tests, an electrocardiogram, urine toxicology screen, and written psychological evaluations.
Participants undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scanning to measure serotonin transporter levels in the brain.
PET uses small amounts of a radioactive chemical called a tracer that "labels" the serotonin transporters in the brain. The tracer used in this study is [11C]DASB. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the subject's head still during the scan so the images will be clear. A brief scan is done just before the radioactive tracer is injected. This scan provides measures of the brain that will help in the precise calculation of information from subsequent scans. After the tracer is injected through a catheter (plastic tube) placed in the arm, pictures are taken for about 2 hours.
MRI uses a magnetic field and radio waves to produce pictures of brain structure. The subject lies on a bed that slides into the tube-like scanner, wearing earplugs to muffle loud noises the machine makes when the magnetic fields are switched. The scan takes about an hour, during which time the subject can communicate with the technician.
調査の概要
状態
条件
詳細な説明
Alcoholism is characterized by the inability of individuals to regulate their consumption of alcohol appropriately. Serotonergic dysfunction has been implicated in the pathophysiology of this illness. Serotonin transporters (SERT) critically regulate the tone of serotonergic transmission (Gobbi et al 2001). In a brain imaging study using the SPECT radioligand, [123I] Beta-CIT, male alcoholics who had abstained from alcohol for more than four weeks, had significantly reduced serotonin transporters in the raphe area of the brainstem compared to healthy control subjects (Heinz et al 1998). However, the [123I] Beta-CIT ligand, binds with high affinity to both the dopamine transporter (DAT) and SERT. Binding of [123I] Beta-CIT in regions rich in SERT or DAT have been attributed to SERT and DAT respectively but in regions of mixed innervation (e.g. cortical regions), it is not possible to distinguish between SERT and DAT.
[11C]DASB is a PET ligand with high affinity for SERT with almost 1,000 fold selectivity versus DAT. Using this tracer, we will be able to measure SERT binding in cortical and subcortical brain regions including those with mixed innervation. [11C] DASB PET studies in humans (Houle et al 2000; Meyer et al 2001) indicate the feasibility of quantifying SERT binding in SERT rich regions. In the current protocol, we plan to use PET imaging with the radioligand, [11C] DASB, for serotonin transporter (SERT) to delineate regional abnormalities in SERT binding in two subject groups consisting of 30 patients with alcoholism and 30 healthy volunteers. Our goal of the present study is to further our understanding of the roles of the serotonergic systems in the pathophysiology of alcoholism.
研究の種類
入学
連絡先と場所
研究場所
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institute of Mental Health (NIMH)
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
- ELIGIBILITY CRITERIA:
Alcoholic and healthy subjects will be recruited from those screened by Dr. Daniel Hommer using either protocol (Protocol number 98-AA-0009) which is used to identify and recruit adult participants who meet DSM-IV criteria for alcohol dependence, alcohol abuse and healthy controls or protocol (Protocol number 05-AA-0121) assessment and treatment of people with alcohol drinking problems.
As stated in protocol 98-AA-0009, subjects will be recruited primarily from the Washington, DC metropolitan area through newspaper advertisements. These have been approved by the NIAAA IRB in the past and have not changed. As necessary these advertisements which are now primarily published in the Washington Post Health Section, will be reviewed and revised. Any revisions will be presented to the IRB. Subjects will also be recruited through outreach to health care professionals and treatment facilities throughout Northern Virginia, West Virginia and the Washington, DC and Baltimore metropolitan areas. Patient referrals for sources throughout the U.S. and on occasion international referrals also will be used.
Increased efforts will be made to recruit alcoholic subjects from the Hispanic community. This will take the form of contacts with treatment programs that serve Hispanic populations, as well as through advertising in Spanish language newspapers. We have decided to exclude children from this protocol because the NIH Clinical Center currently does not have any inpatient units capable of treating substance abusing patients who are under the age of 18. Every effort will be made to recruit a similar number of age-matched males and females. The two groups will not be individually matched by age. For example, we will not seek a control subject to match a particular alcoholic patient's age. Instead the two groups will be matched for mean age. We will obtain informed consent from all subjects per NIH guidelines for research studies.
INCLUSION CRITERIA - PATIENTS:
Age: 18-75
DSM-IV criteria for alcohol dependence or alcohol abuse.
INCLUSION CRITERIA - CONTROLS:
Age: 18-75
EXCLUSION CRITERIA:
PATIENTS AND CONTROLS:
Other current DSM-IV Axis I diagnostic criteria than alcohol dependence or alcohol abuse.
Psychotropic medication or other drugs that may cross the blood brain barrier.
Serious organic disease e.g. liver disease.
Claustrophobia.
Pregnancy.
Prior participation in other research protocols within the past year such that a radiation exposure together with the present study would exceed the annual limits.
Any condition that increases risk for MRI (e.g., pacemaker, metallic foreign body in the eye, etc.)
研究計画
研究はどのように設計されていますか？
協力者と研究者
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始
研究の完了
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。